Core Viewpoint - Zai Ding Pharmaceutical (09688.HK) announced the grant of stock options and restricted stock units as part of its 2024 equity incentive plan, indicating a strategic move to incentivize key personnel and align their interests with shareholders [1][2]. Group 1: Stock Options and Restricted Stock Units - The company granted stock options to one grantee for a total of 500 American Depositary Shares (ADS) [1]. - Additionally, 78 grantees received a total of 72,100 ADS in restricted stock units [1]. Group 2: Market Reaction - Following the announcement, Zai Ding Pharmaceutical's stock rose over 2.8% in pre-market trading [2]. - The company received a "Buy" rating from UBS, which may serve as a catalyst for further stock performance [2].
再鼎医药(09688.HK)：授出可认购合共500股美国存托股份的购股权及7.21万股美国存托股份的受限制股份单位